Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1972 1
1973 3
1974 3
1975 2
1976 2
1977 3
1979 3
1980 12
1981 8
1982 8
1983 13
1984 5
1985 4
1986 6
1987 4
1988 1
1989 9
1990 8
1991 10
1992 8
1993 9
1994 7
1995 3
1996 9
1997 3
1998 5
1999 2
2000 5
2001 6
2002 12
2003 12
2004 32
2005 28
2006 28
2007 49
2008 42
2009 39
2010 35
2011 36
2012 33
2013 36
2014 30
2015 40
2016 41
2017 25
2018 32
2019 31
2020 34
2021 31
2022 28
2023 30
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

790 results

Results by year

Filters applied: . Clear all
Page 1
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Murthy RK, et al. N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825569 Clinical Trial.
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Kabraji S, et al. Among authors: murthy rk. Clin Cancer Res. 2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138. Clin Cancer Res. 2023. PMID: 36074155 Free PMC article.
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Lin NU, et al. Among authors: murthy rk. JAMA Oncol. 2023 Feb 1;9(2):197-205. doi: 10.1001/jamaoncol.2022.5610. JAMA Oncol. 2023. PMID: 36454580 Free PMC article. Clinical Trial.
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Curigliano G, et al. Among authors: murthy r. Ann Oncol. 2022 Mar;33(3):321-329. doi: 10.1016/j.annonc.2021.12.005. Epub 2021 Dec 23. Ann Oncol. 2022. PMID: 34954044 Free article. Clinical Trial.
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Modi S, et al. Among authors: murthy rk. J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058843 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Tamura K, et al. Among authors: murthy rk. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29. Lancet Oncol. 2019. PMID: 31047803 Clinical Trial.
Transcriptomes and metabolism define mouse and human MAIT cell populations.
Chandra S, Ascui G, Riffelmacher T, Chawla A, Ramírez-Suástegui C, Castelan VC, Seumois G, Simon H, Murray MP, Seo GY, Premlal ALR, Schmiedel B, Verstichel G, Li Y, Lin CH, Greenbaum J, Lamberti J, Murthy R, Nigro J, Cheroutre H, Ottensmeier CH, Hedrick SM, Lu LF, Vijayanand P, Kronenberg M. Chandra S, et al. Among authors: murthy r. Sci Immunol. 2023 Nov 10;8(89):eabn8531. doi: 10.1126/sciimmunol.abn8531. Epub 2023 Nov 10. Sci Immunol. 2023. PMID: 37948512 Free PMC article.
Future of mental health.
Murthy RS. Murthy RS. Asian J Psychiatr. 2018 Dec;38:A7-A11. doi: 10.1016/j.ajp.2018.11.007. Asian J Psychiatr. 2018. PMID: 30545496 No abstract available.
790 results